Studies investigating the prognostic role of UA (uric acid) in patients with Type 2 diabetes mellitus have given conflicting findings. We undertook the present study to assess the association between UA and outcome in patients with Type 2 diabetes mellitus and CAD (coronary artery disease). The study included 3705 patients with diabetes mellitus and angiography-proven CAD. UA was measured before coronary angiography. The primary outcome was 1-year all-cause mortality. The UA concentration [median (25th-75th quartiles)] was 6.44 mg/dl (5.40-7.70 mg/dl). There were 264 deaths (7.1 %) during follow-up: 45 deaths in patients of the first UA quartile, 43 deaths in patients of the second UA quartile, 51 deaths in patients of the third UA quartile and 125 deaths in patients of the fourth UA quartile {Kaplan-Meier estimates of mortality, 5.1, 4.8, 5.6 and 14.0 % respectively; unadjusted HR (hazard ratio), 2.81 [95 % CI (confidence interval), 2.21-3.58]; P < 0.001 for fourth quartile compared with first-third quartiles combined}. In the multivariable analysis, UA predicted all-cause mortality with an adjusted HR of 1.29 (95 % CI, 1.12-1.48; P < 0.001), for each S.D. increase in the logarithmic scale of UA level. The inclusion of UA in the multivariable model alongside known cardiovascular risk factors and other relevant variables increased the discriminatory power of the model regarding prediction of all-cause mortality [absolute and relative IDI (integrated discrimination improvement) 0.034 and 20.5 % respectively; P < 0.001]. In conclusion, in patients with Type 2 diabetes mellitus and confirmed CAD, elevated levels of UA predict mortality independently of known cardiovascular risk factors.
INTRODUCTION
Patients with Type 2 diabetes mellitus have up to a 4-fold increase in the incidence of CAD (coronary artery disease), which accounts for three-quarters of diabetes-related deaths and is by far the commonest cause of death in patients with diabetes [1] . Risk stratification of patients with diabetes mellitus for CVD (cardiovascular disease) has a major clinical importance. UA (uric acid) has been intensively investigated as a risk predictor in the general population and in various diseases and interest in this biomarker has recently been resurrected. The relationship between UA and diabetes mellitus is complex and poorly investigated. Despite strong evidence linking UA with hyper-insulinaemia and the metabolic syndrome [2, 3] , the role of UA in the pathophysiology, vascular complications and prognosis of patients with diabetes mellitus remains controversial. Prospective data suggested that individuals with higher UA levels are at a higher risk of future diabetes mellitus independently of other risk factors [4] . UA level in patients with diabetes mellitus has been reported to be lower [5] , not different [6] or higher [7] than in patients without diabetes and various confounding factors such as gender, menopausal status and glycaemic control have been suggested to explain these discrepancies [8] . A progressive decrease in the UA level with an increase in hyperglycaemia [8, 9] , a potential uricosuric effect of glucose at high concentrations and a bell-shaped relationship between glucose and UA [10] have all been described. Similarly, studies investigating the prognostic role of UA in diabetes mellitus have also reported conflicting findings [8, [11] [12] [13] [14] [15] . Some studies have reported that UA is an independent predictor of prognosis in patients with diabetes mellitus [8, [11] [12] [13] , whereas others [14, 15] have failed to demonstrate any prognostic role of UA in patients with diabetes. The reasons for such discrepancy remain unknown.
The present study included a large series of patients with diabetes mellitus and angiography-proven CAD and had two aims: (i) to assess whether there is an association between UA and mortality in patients with diabetes mellitus and CAD and whether this association is independent of established cardiovascular risk factors, and (ii) to investigate the strength of association between UA and mortality in various subgroups of patients with diabetes mellitus.
MATERIALS AND METHODS

Patients
This study sample comprised 3705 consecutive patients with Type 2 diabetes mellitus and angiography-proven significant CAD who were treated with PCI (percutaneous coronary intervention) at the Deutsches Herzzentrum in Munich between March 2000 and December 2009. Characteristics of the source sample, clinical diagnostic criteria of CAD and reasons for patients' exclusion have been described in detail in prior publications from our group [16, 17] . In brief, for inclusion in the present study, patients were required to have Type 2 diabetes mellitus and angiography-proven CAD. Irrespective of the status of diabetes, patients with no UA available, acute infections, impaired renal function (serum creatinine 2 mg/dl) or known malignancies with life expectancy less than 1 year) were excluded. Thus, out of 14 713 patients, 3705 patients with diabetes mellitus, CAD and UA available were included in this study. Of these, 2274 patients had stable CAD and 1431 patients had ACSs (acute coronary syndromes). Patients gave written informed consent before recruitment to the study. The study was carried out in accordance with the Declaration of Helsinki and was approved by the institutional ethics committee.
Angiographic evaluation and PCI
Coronary angiography and PCI were performed using standard criteria. Angiographic criterion for significant CAD was the presence of coronary stenoses 50 % lumen obstruction in, at least, one of the three major coronary arteries. The lesion complexity was defined using the modified American College of Cardiology/American Heart Association criteria [18] . B2 and C lesions were considered as complex. LVEF (left ventricular ejection fraction) was calculated with the area-length method using LV (left ventricular) angiograms [19] .
Coronary stents were implanted in 3350 patients (90.4 %) and balloon angioplasty alone was performed in 355 patients (9.6 %). Antiplatelet therapy consisted of periprocedural use of aspirin, loading dose of clopidogrel (300 or 600 mg) and unfractionated heparin followed by maintenance therapy with clopidogrel (75 mg/day for at least 1 month) and aspirin (200 mg/day continued indefinitely).
Definitions
The diagnosis of Type 2 diabetes mellitus was based on the following criteria: history of diabetes with active treatment with insulin or oral hypoglycaemic agents on admission; documentation of an abnormal fasting blood glucose ( 126 mg/dl or 7.0 mmol/l) or glucose tolerance test ( 200 mg/dl or 11.1 mmol/l) according to WHO (World Health Organization) criteria for diabetes [20] ; or a blood glucose >200 mg/dl at any time. Arterial hypertension was diagnosed if the patient was receiving active treatment with anti-hypertensive drugs or if the systolic BP (blood pressure) was 140 mmHg or the diastolic BP 90 mmHg on at least two separate occasions. Hypercholesterolaemia was diagnosed as documented total cholesterol of 220 mg/dl or prior or ongoing treatment with a lipid-lowering agent. Current smokers were those with regular smoking in the prior 6 months. Patients' weight and height were measured during hospital course and BMI (body mass index) was calculated. The GFR (glomerular filtration rate) was estimated according to the Cockcroft-Gault formula [21] .
Biochemical measurements
Collection and transport of blood samples and the protocols and assay used for obtaining UA measurements have been detailed in prior publications [16, 17] . In brief, blood samples were obtained before angiography in all patients. Blood was collected into tubes containing lithium-heparin as anticoagulant (S-Monovette 4.9 ml; Sarstedt). The UA concentration in plasma was determined with an enzymatic colorimetric test using a Cobas Integra 800 analyser (Roche Diagnostics). The measuring range in plasma is 0.20-25 mg/dl (11.9-1500 μmol/l). The reference range for males is 3.4-7.0 mg/dl (202.3-416.5 μmol/l) and for females is 2.4-5.7 mg/dl (142.8-339.2 μmol/l). The concentration of glucose in NaF-preserved plasma samples was measured using the enzymatic reference method with hexokinase. Expected values in fasting plasma samples are 74-109 mg/dl. HbA 1c (glycated haemoglobin) was determined with a method based on the turbidimetric inhibition immunoassay in haemolysed whole blood anticoagulated with tripotassium-EDTA. HbA 1c in the sample reacts with anti-HbA 1c antibody to form soluble antigen-antibody complexes. The reaction starts after the addition of buffered polyhaptens, which react with excess anti-HbA 1c antibodies to form an insoluble complex that can be determined turbidimetrically. ( DCCT/NGSP). The measurements were performed using a Cobas Integra 800 analyser (Roche Diagnostics). Highsensitivity CRP (C-reactive protein) was measured using a fully automated latex-enhanced immunoturbidometric assay on a Cobas Integra 800 analyser (Roche Diagnostics). The CRP assay has an analytical sensitivity of 0.085 mg/l and a measuring range up to 160 mg/l. The upper limit of the reference range in healthy adults is 5 mg/l. Creatinine was measured using a kinetic colorimetric assay based on the compensated Jaffe method. Laboratory personnel were unaware of clinical, angiographic or follow-up data of the patients.
Outcomes and follow-up
The primary outcome analysis was all-cause mortality at 1 year. Secondary outcome analyses were cardiac mortality, non-fatal myocardial infarction or stroke. Information about death was obtained from hospital records, death certificates or phone contact with relatives of the patient or referring physician(s). Cardiac death was defined according to Academic Research Consortium criteria: any death due to proximate cardiac cause (e.g. myocardial infarction, low-output failure and fatal arrhythmia), unwitnessed death, death of unknown cause and all procedure-related deaths, including those related to concomitant treatment [22] . The diagnosis of myocardial infarction required: the development of new abnormal Q waves in two contiguous precordial leads or two adjacent limb leads; or an elevation of CK-MB (creatine kinase-MB) >twice (>three times for the 48 h after a PCI procedure) the upper limit of normal. Stroke required confirmation by CT (computed tomography) or MRI (magnetic resonance imaging) of the head. The follow-up protocol consisted of a phone interview at 1 month, a visit at 6 months and a phone interview at 12 months. Patients who had cardiac complaints during the follow-up underwent a complete clinical, ECG and laboratory evaluation. Collection of follow-up information and adjudication of adverse events were performed by medical staff unaware of UA level.
Statistical analysis
The normality of data distribution was tested with 1-sample Kolmogorov-Smirnov test. Data are presented as median (interquartile range), counts or proportions (%). Continuous data were compared with the Kruskal-Wallis rank-sum test. Categorical data were compared with χ 2 test. Survival analysis was performed with the use of the Kaplan-Meier method and the log-rank test. A multivariable Cox proportional hazards model was used to assess the association between UA and all-cause or cardiac mortality while adjusting for cardiovascular risk factors and other relevant clinical variables. The following variables were entered into the model: age, sex, BMI, diabetes, arterial hypertension, hypercholesterolaemia, smoking, previous myocardial infarction, previous coronary artery bypass surgery, clinical presentation (stable angina against ACS), estimated GFR, CRP, LVEF, multivessel disease, fasting glucose, insulin therapy, diuretic therapy and UA. UA was entered into the model as a continuous variable after logarithmic transformation and the HRs were calculated per S.D. increase of logarithmic UA scale. The proportional hazards assumption was tested by the Grambsch and Therneau method [23] . The end points of all-cause and cardiac mortality were also assessed in several subgroups along with the possible interaction between UA level and the specific subgroup. The discriminatory power of the model regarding all-cause and cardiac mortality was assessed by calculating the IDI (integrated discrimination improvement) in multivariable models [24] . All analyses were performed using S-PLUS (S-plus statistical package; Insightful). A two-tailed P < 0.05 was considered to indicate statistical significance.
RESULTS
Characteristics of patients
The study included 3705 patients with Type 2 diabetes mellitus and CAD. The UA concentration [median (25th-75th quartiles)] was 6.44 mg/dl (5.40-7.70 mg/dl). For the whole group of patients, the UA quartiles were obtained by combining together the respective UA quartiles of women and men. The UA quartile cut-offs in women were: first quartile (<4.96 mg/dl; n = 241), second quartile (4.96 mg/dl to <6.10 mg/dl; n = 237), third quartile (6.10 mg/dl to <7.70 mg/dl; n = 245) and fourth quartile (>7.70 mg/dl; n = 242). The UA quartile cut-offs in men were: first quartile (<5.53 mg/dl; n = 682), second quartile (5.53 mg/dl to <6.54 mg/dl; n = 685), third quartile (6.54 mg/dl to <7.71 mg/dl; n = 687) and fourth quartile (>7.71 mg/dl; n = 686). The main baseline characteristics of patients are shown in Table 1 . With an increase in the UA level there was a significant increase in patients' age, BMI, proportion of patients with prior myocardial infarction and in the levels of serum creatinine and CRP. The proportion of current smokers as well as estimated GFR and LVEF all decreased significantly with an increase in UA level. There was a decrease in both fasting glucose and HbA 1c levels with increasing UA level. There was no difference in the proportions of patients on insulin therapy in various UA quartiles. The proportion of patients on diuretic therapy increased with the increase in UA level (Table 1) .
Clinical outcome
There were 264 deaths (7.1 %) within the first year following PCI. All-cause deaths according to UA quartile were as follows: 45 deaths in patients of the first quartile, 43 deaths in patients of the second quartile, 51 deaths in patients of the third quartile and 125 deaths in patients of the fourth quartile {Kaplan-Meier estimates of mortality, 5.1, 4.8, 5.6 and 14.0 respectively; unadjusted HR, 2.81 [95 % CI (confidence interval), 2.21-3.58]; P < 0.001 for fourth quartile compared with the first-third quartiles combined} ( Figure 1 ). Early (up to 30 days) and late (30 days to 1 year) deaths were also assessed. Within the first 30 days there were 97 deaths: 17 deaths in patients of the first quartile, 13 deaths in patients of the second quartile, 22 deaths in patients of the third quartile and 45 deaths in patients of the fourth quartile (Kaplan-Meier estimates of mortality, 1.9, 1.4, 2.4 and 4.9 % respectively; logrank test P < 0.001). There were 167 deaths between 30 days and 1 year: 28 deaths in patients of the first quartile, 30 deaths in patients of the second quartile, 29 deaths in patients of the third quartile and 80 deaths in patients of the fourth quartile (KaplanMeier estimates of mortality, 3.2, 3.4, 3.2 and 9.1 % respectively; log-rank test P < 0.001). Death rates from 30 day to 1 year were also calculated for 1000 person-years and were as follows: 35.1 deaths in the first UA quartile, 34.0 deaths in the second UA (Figure 2 ). There were 83 cardiac deaths within the first 30 days: 15 deaths in patients of first quartile, 12 deaths in patients of second quartile, 16 deaths in patients of third quartile and 40 deaths in patients of fourth quartile (KaplanMeier estimates of mortality, 1.7, 1.3, 1.7 and 4.4 % respectively; log-rank test P < 0.001). There were 107 cardiac deaths between 30 days and 1 year: 20 deaths in patients of first quartile, 18 deaths in patients of second quartile, 21 deaths in patients of third quartile and 48 deaths in patients of fourth quartile (KaplanMeier estimates of mortality, 2.3, 2.1, 2.4 and 5.6 % respectively; log-rank test P < 0.001).
Non-fatal myocardial infarction occurred in 144 patients: 40 infarctions in the first quartile, 23 infarctions in the second quartile, 40 infarctions in the third quartile and 41 infarctions in the fourth quartile (Kaplan-Meier estimates of infarction occurrence, 4.4, 2.5, 4.4 and 4.6 % respectively (P = 0.081).
Stroke occurred in 34 patients: six strokes in the first quartile, seven strokes in the second quartile, 12 strokes in the third quartile and nine strokes in the fourth quartile (Kaplan-Meier estimates of stroke occurrence, 0.7, 0.8, 1.2 and 1.0 % respectively (P = 0.486).
UA-mortality association after adjustment in multivariable model
The multivariable Cox proportional hazards model was used to test the independence of the association between UA and all-cause and cardiac mortality while adjusting for potential confounders which included traditional cardiovascular risk factors, extent of CAD, ventricular function, status of renal function, metabolic control and inflammatory status (see the Materials and methods section for variables entered into the models). UA was entered into the model as continuous variable after logarithmic transformation. The yield of the multivariable Cox model for all-cause and cardiac mortality is shown in Table 2 . The model showed that UA predicted all-cause mortality with an adjusted HR of 1.29 (95 % CI, 1.12-1.48; P < 0.001) for each S.D. increase in the logarithmic scale of UA level and cardiac mortality with an adjusted HR of 1.15 (95 % CI 1.01-1.36; P = 0.048) for each S.D. increase in the logarithmic scale of UA level.
The discriminatory power of the model regarding all-cause and cardiac mortality was assessed by calculating the IDI of the models without and with inclusion of UA. The inclusion of UA into the multivariable model was associated with a significant increase in the accuracy of the model for prediction of all-cause mortality (absolute IDI, 0.034; relative IDI, 20.5 %; P < 0.001) and a trend for increased accuracy of the model regarding cardiac mortality (absolute IDI, 0.006; relative IDI, 3.7 %; P = 0.061).
Subgroup analysis
All-cause and cardiac mortality was assessed in subgroups obtained by dichotomizing patients according to age (cut-off, 65 years), sex, arterial hypertension, GFR (cut-off, 60 ml/min), BMI (cut-off, 30 kg/m 2 ), LVEF (cut-off, 50 %), CRP (cut-off, 5 mg/l) and fasting glucose (cut-off 126 mg/dl). For this analysis, UA level was dichotomized at fourth quartile (groups with UA or >7.70 mg/dl). UA predicted all-cause mortality across all subgroups. A significant interaction (P = 0.004) between UA and renal function showing a stronger predictive value of UA regarding all-cause mortality in patients with less impaired renal function was observed (Figure 3) . With regard to cardiac mortality, again UA predicted outcomes in all subgroups with the exception of those with preserved LV function. An interaction was observed between UA and renal function (P = 0.019), indicating Figure 3 All-cause mortality in various subgroups of patients Data on BMI, GFR, LVEF and CRP were available in 99.8 % (n = 3698), 86 % (n = 3178), 99.8 % (n = 3699) and 99.1 % (n = 3672) of the patients respectively. Abbreviations: Glc, glucose; No., number; P int , P for interaction. a stronger association between UA and cardiac mortality in patients with less impaired renal function (Figure 4 ). Moreover, there was a strong trend for an interaction between UA and fasting glucose (P = 0.079), implying a possible stronger association between UA and cardiac mortality in diabetes mellitus patients with worse metabolic control (Figure 4 ).
DISCUSSION
The main findings of the present study can be summarized as follows. First, elevated UA level is an independent predictor of both all-cause mortality and cardiac mortality in patients with diabetes mellitus and CAD. The association between UA and mortality was independent of cardiovascular risk factors, inflammatory status, metabolic control and renal function. Adding UA in multivariable models alongside the other relevant variables increased the power of models to predict all-cause but not cardiac mortality. Secondly, UA predicted an increased risk of all-cause and cardiac mortality across a wide range of subgroups of patients with diabetes mellitus and CAD. Thirdly, the association between UA and all-cause and cardiac mortality was stronger in patients with preserved renal function, suggesting that the presence of impaired renal function may attenuate the association between UA and mortality in patients with diabetes mellitus and CAD. There was a strong trend for an interaction between metabolic control and UA level, suggesting a stronger association between UA and cardiac mortality in patients with poor metabolic control. Previous studies addressing the prognostic role of UA in patients with diabetes have given conflicting results [8, [11] [12] [13] [14] [15] . A recent cohort study of 2726 patients with diabetes mellitus, who were followed for a median of 4.7 years showed a significant 27 % increase in the adjusted risk for cardiovascular mortality with higher UA levels [11] . However, the association between UA and all-cause mortality was not significant. The CASTEL (Cardiovascular Study in the Elderly) study demonstrated a significant association between UA and CAD mortality in elderly ( 65 years) patients with Type 2 diabetes mellitus over a 12-year follow-up [12] . Along similar lines, a retrospective cohort analysis of 535 patients with diabetes mellitus showed that UA predicted mortality regardless of gender, HbA 1c , renal function and diuretic use [8] . Other studies have shown that UA predicts mortality either preferentially or solely in patients with diabetes mellitus [9, 13] . In the Rancho Bernardo Study, UA predicted cardiovascular mortality in subjects with impaired glucose tolerance and diabetes mellitus but not in normoglycaemic patients [13] . Contrary to these studies, several other studies failed to demonstrate any association between UA and mortality in patients with diabetes [14, 15] . The Freemantle Diabetes Study failed to find an independent association between UA and all-cause or cardiovascular mortality after adjustment for relevant variables in 1268 patients with diabetes mellitus over a mean follow-up of 10.3 years [14] . In congruence with the present study, a recent population-based study of 1540 patients with diabetes mellitus could not demonstrate an independent association between UA level and cardiovascular mortality over a 15-year follow-up [15] . An observed association between UA and all-cause mortality was mostly due to an increase in the risk of non-cardiovascular mortality, especially because of an increase in mortality due to neoplastic diseases with the increase in the UA level [15] . To our knowledge the present study represents the largest series of patients with diabetes mellitus and angiography-proven CAD in which the association between UA level and mortality has been investigated. Our study demonstrated that elevated UA level is a significant and independent correlate of all-cause and cardiac mortality. Thus, our findings support those prior studies showing an association between elevated UA levels and mortality in patients with diabetes mellitus. Nevertheless, although the association between UA and all-cause or cardiac mortality remained significant after adjustment for cardiovascular risk factors and other relevant variables deemed to affect prognosis, adding UA in multivariable models increased the power of models to predict all-cause but not cardiac mortality.
Mechanisms by which elevated UA level increase the risk of adverse events in patients with diabetes mellitus remain poorly understood. Deleterious vascular effects by which elevated UA levels may increase various adverse events have been extensively studied and reviewed recently [3] . Hypothetically, it may be said that diabetes mellitus and elevated UA levels may be synergistic in accentuating endothelial dysfunction, increased inflammatory burden and oxidative stress (UA may be pro-oxidant in the setting of the metabolic syndrome). Since endothelium is one of the major sites of UA production in the cardiovascular system [25] , it may be a preferential target for adverse events in patients with diabetes with elevated UA level. In fact 72 % of deaths in patients of our study were due to cardiac causes. A recent study of patients with diabetes mellitus showed that the incidence of fatal and non-fatal stroke increased significantly with the increase in UA level [26] . In patients with the metabolic syndrome, elevated UA level is associated with increased risk of myocardial infarction and sudden cardiac death [27] . Other studies have shown that elevated UA level increased the incidence of micro-and macro-angiopathies (and as a consequence the incidence of impaired renal function and CAD) in patients with diabetes mellitus [28] . These adverse events promoted by elevated UA level in patients with diabetes mellitus could explain, at least in part, the increased risk of mortality in these patients.
Subgroup analyses of patients with diabetes mellitus in the setting of present study offer some interesting and important findings. First, we found that elevated UA level predicted an increased risk of mortality across all subsets of patients. Secondly, interaction testing between various subgroups and UA level regarding mortality prediction showed that the association between UA and mortality was stronger in patients with preserved (or less impaired) renal function. We believe that this finding is novel and not reported before in patients with diabetes mellitus. A report from the ARIC (Atherosclerosis Risk in Communities) study has shown that the presence of kidney disease attenuates the association between UA and mortality and that elevated UA level is associated with hyperinsulinaemia and increased risk of mortality only in subjects without kidney disease [29] . Although, the reasons for the observed interaction between renal function and UA level remain unknown, a hypothesis may be offered. The circulating levels of UA depend on UA production (including dietary purine intake) and rate of UA elimination (mostly by renal excretion) and an elevated UA level may result from increased production, reduced elimination or both. Since renal function is by far the most important predictor of UA level [12, 30] , we suppose that, in patients with impaired renal function, elevated UA level is mostly due to retention. We hypothesize that hyperuricaemia by retention is more benign than hyperuricaemia by increased production. It has firmly been established that xanthine oxidase -the final enzyme involved in UA synthesis -is a major producer of oxygen-free species [31] . Thus, in patients with preserved renal function, elevated UA level might be associated with more oxidative stress due to concomitant production of oxygenfree radical species by overexpressed xanthine oxidase which may explain the poorer outcome. Conversely, in patients with impaired renal function hyperuricaemia might be less deleterious and less strongly associated with outcome if adjusted for renal function. Other studies seem to offer support to this hypothesis. It has been demonstrated that in patients with congestive heart failure, haemodynamic impairment is associated with up-regulated xanthine oxidase activity but not with UA level [32] . Further studies are needed to corroborate this hypothesis. Thirdly, we found a strong trend for an interaction between metabolic control and UA level, in which the association between UA and cardiac mortality was stronger in patients with poorer metabolic control. Although this finding would have important implications, the level of statistical significance and the potential for multiple testing to detect chance findings warrant caution in its interpretation.
The present study has limitations. A longer follow-up would be desirable. However, at the end of follow-up, the differences between the groups according to UA level were highly significant and the survival curves expanded over the entire follow-up period. Consequently, further expansion of survival curves would be expected to occur with a longer follow-up. Moreover, several studies have reported significant differences in clinical outcome only months after elevated UA levels were observed [28, 33] . The present study included patients with diabetes mellitus and confirmed CAD. It has been shown that the presence of CAD may strengthen the association between UA and mortality [34] . Since the presence or absence of CAD is an important confounder, we emphasize that these findings belong to patients with diabetes mellitus and CAD and may not be extrapolated to patients with diabetes mellitus but without clinical CAD. Finally the metabolic control was assessed only by fasting glucose and not by HbA 1c due to incomplete data.
In conclusion, the results of the present study have shown that elevated UA is an independent predictor of all-cause and cardiac mortality in patients with diabetes mellitus and CAD. The inclusion of UA in multivariable models alongside the other relevant variables increased the power of models to predict allcause but not cardiac mortality. UA predicted an increased risk of all-cause and cardiac mortality across various subgroups of patients with a stronger association with mortality in patients with preserved renal function. An observed trend for a stronger association between UA and cardiac mortality in patients with poorer metabolic control needs further investigation.
CLINICAL PERSPECTIVES
r Deaths due to CAD account for three-quarters of diabetesrelated mortality. Studies that have investigated the prognostic role of UA in patients with Type 2 diabetes mellitus have given conflicting results.
r We undertook the present study to assess the association between UA and mortality in a large series of patients with diabetes and angiography-confirmed CAD. We found an association between UA level and 1-year all-cause and cardiac mortality, which was independent of cardiovascular risk factors, inflammatory status, metabolic control and renal function. UA predicted an increased risk of all-cause and cardiac mortality across a wide variety of subgroups of patients with diabetes and CAD. The inclusion of UA in multivariable models alongside the other relevant variables increased the discriminatory power of these models to predict all-cause mortality.
r The finding of a close association between UA and mortality suggests that UA may be used in the risk-stratification schemes of patients with diabetes.
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